Advertisement
U.S. markets closed

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5709-0.0101 (-1.74%)
At close: 04:00PM EST
0.5810 +0.01 (+1.77%)
After hours: 07:32PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.5810
Open0.5632
Bid0.5801 x 1000
Ask0.6200 x 1300
Day's Range0.5600 - 0.6169
52 Week Range0.5080 - 3.2800
Volume129,158
Avg. Volume119,558
Market Cap10.459M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-2.6400
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TRVN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Trevena, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    3 years agoMorningstar
View more
  • GlobeNewswire

    Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

    CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,77

  • GlobeNewswire

    Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

    CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 s

  • GlobeNewswire

    Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

    -- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the S1P1 receptor without associated lymphopenia -- CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders